<DOC>
	<DOCNO>NCT01851499</DOCNO>
	<brief_summary>Randomized , double-blinded , placebo-controlled , parallel group study ultramicronized PEA ( Normast ) 600 mg x 2 daily correspond placebo week baseline period follow 1 x 12 week treatment period .</brief_summary>
	<brief_title>Ultramicronized PEA ( Normast ) Spinal Cord Injury Neuropathic Pain</brief_title>
	<detailed_description>Study design : Randomized , double-blinded , placebo-controlled , parallel , multi-center study ultramicronized PEA ( Normast ) week baseline period follow 1 x 12 week treatment period . Methodology : Given Normast 600mg x 2 daily correspond placebo keep dose 12 week .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<criteria>Patients age 18 year and/or belowlevel neuropathic pain least 3 month due trauma disease spinal cord cauda equina ( least 6 month old ) mean pain intensity 4 9 010 point numeric rating scale ( NRS ) oneweek baseline period eligible study know concomitant severe cerebral damage , terminal illness , plan surgery , pregnancy lactation , alcohol substance abuse , hypersensitivity PEA carrier , psychiatric disease except depression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Neuropathic pain follow spinal cord injury</keyword>
</DOC>